300676.SZ Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 10:04):

Stats
Šios dienos apimtis	3.08M
Vidutinė apimtis	3.48M
Rinkos kapitalizacija	16.86B
EPS	CNY0.0445 ( 2023-10-27 )
Kita pelno data	( CNY0 ) 2024-05-09
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	178.83
ATR14	CNY0.0310 (0.08%)

Tūris Koreliacija

Ilgas: 0.39 (neutral)

Trumpas: -0.52 (weak negative)

Signal:(50.672) Neutral

BGI Genomics Co., Ltd. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

BGI Genomics Co., Ltd. Koreliacija - Valiuta/Žaliavos

0.18
( neutral )

0.07
( neutral )

0.00
( neutral )

-0.43
( neutral )

0.25
( neutral )

BGI Genomics Co., Ltd. Finansinės ataskaitos

Annual	2023
Pajamos:	CNY4.35B
Bruto pelnas:	CNY2.17B (49.94 %)
EPS:	CNY0.220

FY	2023
Pajamos:	CNY4.35B
Bruto pelnas:	CNY2.17B (49.94 %)
EPS:	CNY0.220

FY	2022
Pajamos:	CNY7.05B
Bruto pelnas:	CNY3.69B (52.36 %)
EPS:	CNY1.960

FY	2021
Pajamos:	CNY6.77B
Bruto pelnas:	CNY3.93B (58.09 %)
EPS:	CNY3.56

Financial Reports:

No articles found.

BGI Genomics Co., Ltd.

BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2. The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.